Anders Gabrielsen, MD, PhD, is a clinical specialist-physician in cardiology and inpatient medicine from Karolinska University Hospital, has attended the University of Copenhagen and researched at Karolinska Institutet in the field of translational and molecular cardiovascular research. In parallel with his associate professor of cardiology at Karolinska Institutet, Anders Gabrielsen has worked internationally with drug development and medical positioning of pharmaceuticals in the market, including within Bayer as a medical adviser and global specialist in Medical Affairs. Anders Gabrielsen has been working for Novartis since 2016 as Director of the Global Medical Affairs Unit for Cardiomedical Drugs with a special responsibility for the CANTOS study. Since May 2023 is Anders Head & VP Clinical Development at Ribocure AB.
Back